{"doi":"10.1179/joc.2006.18.5.538","title":"A Prospective Randomized Study of Irinotecan (CPT-11), Leucovorin (LV) and 5-Fluorouracil (5FU) versus Leucovorin and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma","abstract":null,"journal":"Journal of Chemotherapy","year":2006,"id":601950,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1543581,"name":"G. Papaxoinis","orcid":null,"position":1,"is_corresponding":false},{"id":1543582,"name":"V. Michalaki","orcid":null,"position":2,"is_corresponding":false},{"id":1543583,"name":"D. Mouratidou","orcid":null,"position":3,"is_corresponding":false},{"id":1543584,"name":"CH. Andreadis","orcid":null,"position":4,"is_corresponding":false},{"id":1543585,"name":"N. Tsavaris","orcid":null,"position":5,"is_corresponding":false},{"id":1543586,"name":"A. Pafiti","orcid":null,"position":6,"is_corresponding":false},{"id":1543580,"name":"C. Gennatas","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Prospective Randomized Study of Irinotecan (CPT-11), Leucovorin (LV) and 5-Fluorouracil (5FU) versus Leucovorin and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma","abstract":"The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma. One hundred and sixty patients were randomized; 80 patients (group A) received LV 20 mg/m(2) bolus i.v. and 5FU 425 mg/m(2) bolus i.v. on days 1-5, every 28 days; 80 patients (group B) received CPT-11 80 mg/m(2) (30-90 min i.v. infusion), followed by LV 20 mg/m(2) bolus i.v. and 5FU 425 mg/m(2) bolus i.v. on days 1, 8, 15, 22, 29, and 36, every 8 weeks. The overall response rate was 30% and 47.5% in groups A and B respectively. Progression-free survival was significantly higher in the triple-drug combination arm (median 7.5 vs. 4.5 months; p= 0. 0335). However, overall survival did not differ significantly between the two arms (15 months vs. 14 months for the groups B and A respectively; p=0.3531). The main grade 3 adverse events were diarrhea (19%, in group A vs. 35% in group B; p=0.032) and mucositis (2% vs. 14%; p=0.017). The regimen containing irinotecan showed activity in advanced colorectal cancer. The overall safety data confirm this combination as a well-tolerated treatment.","is_dataset_classified":null,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"17127232","pmcid":null,"openalex_id":"https://openalex.org/W2113053109","authors":[],"funders":[],"total_grants":0,"fwci":0.296,"citation_percentile":0.59947988,"influential_citations":0,"citation_trend":[{"year":2013,"count":1},{"year":2015,"count":1},{"year":2016,"count":1},{"year":2017,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883","host_type":"publisher"},{"url":"https://doi.org/10.1179/joc.2006.18.5.538","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/17127232","host_type":"repository"}],"fields_of_study":["Colorectal Cancer Treatments and Studies","Gastric Cancer Management and Outcomes","Colorectal Cancer Surgical Treatments"],"mesh_terms":["Irinotecan","Adult","Aged","Antineoplastic Agents","Antineoplastic Combined Chemotherapy Protocols","Camptothecin","Carcinoma","Leucovorin","Female","Fluorouracil","Humans","Male","Middle Aged","Colorectal Neoplasms","Survival Analysis","Treatment Outcome","Disease-Free Survival"],"keywords":["Fluorouracil","Irinotecan","Medicine","Internal medicine","Colorectal cancer","Oncology","Chemotherapy","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T17:52:48.586222Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}